Home \ News \ Virtual Press Conference: COVID-19 Vaccines for Children 5-11 Years Old – 10/29/2021

More

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Virtual Press Conference: COVID-19 Vaccines for Children 5-11 Years Old – 10/29/2021

NOW PLAYING

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

CDC Statement on ACIP Booster Recommendations

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Tense decision-making as CDC joins FDA in recommending Pfizer booster shot for 65 & up, people at high risk and those with occupational exposure to COVID-19

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Ten scientific reasons in support of airborne transmission of SARS-CoV-2

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months, study shows

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Top COVID-19 doctors and scientists privately asked the Biden administration to scrap its booster-shot plan, report says

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Is my immunity waning? Doctors advise Pfizer vaccine recipients not to worry

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

FDA review finds Moderna’s booster dose of its coronavirus vaccine strengthens disease-fighting response

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

Myths and Facts about COVID-19 Vaccines

First-of-its-kind COVID-19 antibody treatment: FDA authorization requested

TENSE DECISION MAKING BETWEEN CDC AND FDA

Virtual Press Conference: COVID-19 Vaccines for Children 5-11 Years Old – 10/29/2021

TVNET3 November 2, 2021 3:43 pm

Join us for a virtual press conference to discuss the FDA’s emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age. Acting FDA Commissioner Dr. Janet Woodcock and FDA’s Center for Biologics Evaluation and Research Director Dr. Peter Marks will be taking questions.

Category: News

About The Author

TVNET3 -